Trial Profile
A Randomized, Double-Blind, Tw0-Period Crossover Study to Assess the Efficacy and Safety of the Ampakine Compound, CX717, Versus Placebo in Adults With Attention-Deficit Hyperactive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs CX 717 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors RespireRx Pharmaceuticals
- 08 Nov 2005 New trial record.